Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Florbetaben F18 · 1 trial · 1 indication
Percent Test-Retest variability (%) of cardiac 18F florbetaben PET
| Arm | Type | Description |
|---|---|---|
| Patients with cardiac disease | EXPERIMENTAL | All eligible AL, ATTR and non-CA patients will receive two injections of the investigational imaging agent florbetaben: at a baseline PET imaging session and at a follow-up PET imaging session to evaluate the test-retest imaging characteristics. 5 patients of each group will be required. |
| Name | Type | Description |
|---|---|---|
| Florbetaben F18 | DRUG | Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq). |
Inclusion Criteria: * Inclusion criteria (for all subjects): * Males and females aged ≥40 years * Able to understand, sign, and date written informed consent * Written informed consent must be obtained before any assessment is performed * Female subjects must be documented by medical recor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc | ALNY | 5 | PHASE3 | Vutrisiran, Sterile Normal Saline |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 4 | PHASE3 | NNC6019-0001 |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Eplontersen |
| Ionis Pharmaceuticals, Inc. | IONS | 3 | PHASE3 | Eplontersen |
| Intellia Therapeutics, Inc. | NTLA | 2 | PHASE3 | NTLA-2001 |
| Pfizer Inc. | PFE | 1 | - | Undisclosed |
Florbetaben F18 is an investigational small molecule being studied for use in Cardiac Amyloidosis, a condition where abnormal protein deposits accumulate in the heart. It is currently in Phase 1 clinical development, with an active trial evaluating its test-retest reliability as an imaging agent for this disease.
Florbetaben F18 is a radioactive tracer that binds to amyloid deposits, which are abnormal protein aggregates that accumulate in tissues. In the context of Cardiac Amyloidosis, it is designed to detect these deposits in the heart, potentially aiding in diagnosis and monitoring of the condition.
Florbetaben F18 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. The company is conducting a Phase 1 clinical trial to evaluate the agent's performance in patients with Cardiac Amyloidosis.
Florbetaben F18 is in Phase 1 clinical development. It is an investigational agent, not yet approved by regulatory authorities, and is currently being studied in a single active trial for Cardiac Amyloidosis. The trial is recruiting participants in the United Kingdom.
Florbetaben F18 is being evaluated in a Phase 1 clinical trial with the identifier NCT06790394, titled 'Test-retest Study With [18F]FBB in Cardiac Amyloidosis.' This single-arm, uncontrolled study is recruiting 15 participants aged 40 years and older in the United Kingdom.
Yes, Florbetaben F18 is also known as [18F]FBB, as indicated by the clinical trial title. The compound is a fluorine-18 labeled tracer, and the abbreviation FBB refers to florbetaben, the active pharmaceutical ingredient.